Hypermethylation of the tumor necrosis factor receptor superfamily 6 (APT1, Fas, CD95/Apo-1) gene promoter at rel/nuclear factor κB sites in prostatic carcinoma

Molecular Carcinogenesis

Volumn 32, Issue 1, 2001, Pages 36-43

  Santourlidis, Simon ^b   Warskulat, Ulrich ^a   Florl, Andrea R ^b   Maas, Simone ^b   Pulte, Thomas ^b   Fischer, Johannes ^b   Müller, Wolfram ^b   Schulz, Wolfgang A ^b  

^a HEINRICH HEINE UNIVERSITY   (Germany)

^b NONE

Author keywords

Apoptosis; Bladder cancer; DNA methylation; Polymerase chain reaction; Transcriptional repression; Transfection assay

Indexed keywords

BISULFITE; CELL PROTEIN; FAS ANTIGEN; IMMUNOGLOBULIN ENHANCER BINDING PROTEIN; PROTEIN APT1; TRANSCRIPTION FACTOR REL; TUMOR NECROSIS FACTOR RECEPTOR; UNCLASSIFIED DRUG;

ADULT; ADVANCED CANCER; AGED; APOPTOSIS; ARTICLE; BINDING SITE; BLADDER CARCINOMA; CANCER CELL CULTURE; CLINICAL ARTICLE; CONTROLLED STUDY; CPG ISLAND; DNA METHYLATION; GENE INACTIVATION; HUMAN; HUMAN CELL; HUMAN TISSUE; MALE; METASTASIS; MULTIGENE FAMILY; NUCLEOTIDE SEQUENCE; PRIORITY JOURNAL; PROMOTER REGION; PROSTATE CARCINOMA; REVERSE TRANSCRIPTION POLYMERASE CHAIN REACTION; SEQUENCE ANALYSIS;

EID: 0034795875     PISSN: 08991987     EISSN: None     Source Type: Journal    
DOI: 10.1002/mc.1062     Document Type: Article

References (26)

1. CD95(APO-1/Fas)-mediated apoptosis in normal and malignant liver, colon, and hematopoietic cells
2. Lymnphocyte apoptosis induced by CD95 (APO-1/FAS) ligand-expressing tumor cells: A mechanism of immune evasion
3. Down-regulation of Fas gene expression in colon cancer is not a result of allelic loss or gene rearrangement
4. CD95 ligand expression in dedifferentiated breast cancer
5. Regulation of CD95 (APO-1/FAS) ligand and receptor expression in squamous-cell carcinoma by interferon-γ and cisplatin
6. CD95 ligand expression as a mechanism of immune escape in breast cancer
7. Identification of a candidate tumour suppressor gene, MMAC1, at chromosome 10q23.3 that is mutated in multiple advanced cancers
8. Loss of the chromosomal region 10q23-25 in prostate cancer
9. Frequent loss of heterozygosity on chromosome 10q in muscle-invasive transitional cell carcinomas of the bladder
10. Alterations of Fas (APO-1/CD95) gene in transitional cell carcinomas of urinary bladder
11. Cytidine methylation or regulatory sequences near the π-class glutathione S-transferase gene accompanies human prostatic carcinogenesis
12. High frequency of alterations in DNA methylation in adenocarcinoma of the prostate
13. Cytometric analysis of Fas and Bcl-2 expression in normal prostatic epithelium and prostate cancer
14. Modulation of growth and apoptosis response in PC-3 and LNCAP prostate-cancer cell lines by Fas
15. Camptothecin sensitizes androgen-independent prostate cancer cells to anti-Fas-induced apoptosis
16. Oncogenic Ras inhibits Fas ligand-mediated apoptosis by downregulating the expression of Fas
17. Identification of a silencer, enhancer and basal promoter region in the human CD95 (Fas/APO-1) gene
18. NFkappaB mediates apoptosis through transcriptional activation of (CD95) in adenoviral hepatitis
19. DNA methylation and retrovirus expression
20. DNA methylation and expression of L1 LINE and HERV-K provirus sequences in urothelial and renal cell carcinoma
21. Inactivation of tumor suppressor genes and deregulation of the c-myc gene in urothelial cancer cell lines
22. Frequent and heterogenous expression of cyclin-dependent kinase inhibitor WAF1/p21 protein and mRNA in urothelial carcinoma
23. Promoter region methylation does not account for the frequent loss of expression of the Fas gene in colorectal carcinoma
24. Methylation-induced repression: Belts, braces, and chromatin
25. Constitutive activation of Ikappa B kinase alpha and NF-kappaB in prostate cancer cells is inhibited by ibuprofen
26. Loss of Fas (CD95/APO-1) expression by antigen-specific cytotoxic T cells is reversed by inhibiting DNA methylation